Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 5018 results found since Jan 2013.

A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity)
Conclusions Though this is not a comprehensive summary of malignancies in PIDDs, or even lymphoproliferative disease in this area, this review summarizes the Medline-indexed published reports of B and T lymphomas in patients with PIDDs. This report highlights the diversity of malignant lymphoproliferative disorders in setting of PIDDs, and its associated challenges of diagnosis and treatment. The pathological classification and nomenclature for the lymphoid malignancies with variably reported and postulated underlying mechanisms were inconsistent and inadequate for many of these published reports. A wide range of treatmen...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Biologic therapies and bone loss in rheumatoid arthritis
ConclusionTreatment with biologic drugs is associated with the decrease in bone loss. Studies with anti-TNF blocking agents show preservation or increase in spine and hip BMD and also a better profile of bone markers. Most of these studies were performed with infliximab. Only three epidemiological studies analyzed the effect on fractures after anti-TNF blocking agent ’s treatment. IL-6 blocking agents also showed improvement in localized bone loss not seen with anti-TNF agents. There are a few studies with rituximab and abatacept. Although several studies reported favorable actions of biologic therapies on bone protectio...
Source: Osteoporosis International - January 27, 2017 Category: Orthopaedics Source Type: research

Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome
CONCLUSIONS: This updated review strengthened the evidence that immunosuppressive therapy is probably superior to non-immunosuppressive therapy in inducing remission and reducing the number of patients that progress to ESKD. However, these benefits need to be balanced against the side effects of immunosuppressive drugs. The number of included studies with high-quality design was relatively small and most studies did not have adequate follow-up. Clinicians should inform their patients of the lack of high-quality evidence. An alkylating agent (cyclophosphamide or chlorambucil) combined with a corticosteroid regimen had short...
Source: Cochrane Database of Systematic Reviews - November 15, 2021 Category: General Medicine Authors: Thilo C von Groote Gabrielle Williams Eric H Au Yizhi Chen Anna T Mathew Elisabeth M Hodson David J Tunnicliffe Source Type: research

Interventions for focal segmental glomerulosclerosis in adults
CONCLUSIONS: No RCTs, which evaluated corticosteroids, were identified although the KDIGO guidelines recommend corticosteroids as the first treatment for adults with FSGS. The studies identified included participants with steroid-resistant FSGS. Treatment with cyclosporin for at least six months was more likely to achieve complete remission of proteinuria compared with other treatments but there was considerable imprecision due to few studies and small participant numbers. In future studies of existing or new interventions, the investigators must clearly define the populations included in the study to provide appropriate r...
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Elisabeth M Hodson Aditi Sinha Tess E Cooper Source Type: research

Interventions for minimal change disease in adults with nephrotic syndrome
CONCLUSIONS: This updated review has identified evidence for the efficacy and adverse effects of CNIs and EC-MPS with or without reduced-dose prednisolone compared with prednisolone alone for the induction of remission in adults with MCD and nephrotic syndrome with some reductions in steroid-associated adverse events. RCT data on the efficacy and adverse effects of rituximab in adults with MCD are awaited. Further, adequately powered RCTs are required to determine the relative efficacies of CNIs and EC-MPS and to evaluate these medications in patients with relapsing or steroid-resistant disease.PMID:35230699 | DOI:10.1002/...
Source: Cochrane Database of Systematic Reviews - March 1, 2022 Category: General Medicine Authors: Karolis Azukaitis Suetonia C Palmer Giovanni Fm Strippoli Elisabeth M Hodson Source Type: research

Interventions for focal segmental glomerulosclerosis in adults
CONCLUSIONS: No RCTs, which evaluated corticosteroids, were identified although the KDIGO guidelines recommend corticosteroids as the first treatment for adults with FSGS. The studies identified included participants with steroid-resistant FSGS. Treatment with cyclosporin for at least six months was more likely to achieve complete remission of proteinuria compared with other treatments but there was considerable imprecision due to few studies and small participant numbers. In future studies of existing or new interventions, the investigators must clearly define the populations included in the study to provide appropriate r...
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Elisabeth M Hodson Aditi Sinha Tess E Cooper Source Type: research

Vaccination against SARS-CoV-2 in patients with multiple sclerosis
CONCLUSION: The data available make it possible to recommend mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. In patients on fingolimod, cladribine, alemtuzumab, ocrelizumab and rituximab, vaccination prior to the initiation of medication administration would be recommendable whenever possible.PMID:33764494 | DOI:10.33588/rn.7207.2021097
Source: Revista de Neurologia - March 25, 2021 Category: Neurology Authors: L Costa Frossard-Fran ça J M Garc ía-Domínguez I Moreno-Torres J Fort ún L M Villar V Meca-Lallana Source Type: research